Immunotherapy for Primary Immunodeficiency Diseases

Medical Clinics of North America

Volumn 96, Issue 3, 2012, Pages 433-454

  Wood, Philip ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antibody deficiency; C1 inhibitor; Common variable immunodeficiency; Hereditary angioedema; Immunoglobulin therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; BIOLOGICAL PRODUCT; BRADYKININ; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ETANERCEPT; HUMAN IMMUNOGLOBULIN; ICATIBANT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; INTRATECT; KALLIKREIN; PLACEBO; RITUXIMAB; SUBGAM; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACKACHE; BACTERIAL INFECTION; BLOOD; BLOOD ANALYSIS; BLOOD DONOR; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; BRONCHOSPASM; CANNULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONSENSUS; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATION; DIAGNOSTIC TEST; DISEASE TRANSMISSION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC EVALUATION; EPIDEMIC; EVIDENCE BASED MEDICINE; FEVER; FRACTIONATION; GRANULOMATOSIS; HEALTH CARE QUALITY; HEREDITY; HOME CARE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LIFE EXPECTANCY; LOW DRUG DOSE; MORBIDITY; NONHUMAN; PNEUMONIA; PRIMARY ANTIBODY DEFICIENCY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGOR; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; THERAPY DELAY; URTICARIA;

ADRENERGIC BETA-ANTAGONISTS; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; COST-BENEFIT ANALYSIS; DELAYED DIAGNOSIS; DISEASE TRANSMISSION, INFECTIOUS; FILTRATION; GRANULOMA; HOME INFUSION THERAPY; HUMANS; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; KALLIKREINS; NANOTECHNOLOGY; PEPTIDES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY CONTROL; QUALITY OF LIFE; RECOMBINANT PROTEINS; SELF ADMINISTRATION; TECHNOLOGY, PHARMACEUTICAL;

EID: 84862312474     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.04.010     Document Type: Review

References (90)

1. Conley M.E., Broides A., Hernandez-Trujillo V., et al. Genetic analysis of patients with defects in early B-cell development. Immunol Rev 2005, 203:216-234.
2. Kracker S., Gardes P., Durandy A. Inherited defects of immunoglobulin class switch recombination. Adv Exp Med Biol 2010, 685:166-174.
3. Notarangelo L.D., Fischer A., Geha R.S., et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009, 124(6):1161-1178.
4. Hermaszewski R.A., Webster A.D. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993, 86(1):31-42.
5. Cunningham-Rundles C., Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999, 92(1):34-48.
6. Kainulainen L., Varpula M., Liippo K., et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999, 104(5):1031-1036.
7. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004, 83(4):254-263.
8. Bruton O.C. Agammaglobulinemia (congenital absence of gamma globulin); report of a case [passim]. Med Ann Dist Columbia 1953, 22(12):648-650.
9. Church J.A., Leibl H., Stein M.R., et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 2006, 26(4):388-395.
10. Shah S.R. A newer immunoglobulin Intravenous (IGIV) Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care. Expert Opin Biol Ther 2008, 8(6):799-804.
11. Stein M.R., Nelson R.P., Church J.A., et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 2009, 29(1):137-144.
12. Berger M., Pinciaro P.J., Althaus A., et al. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol 2010, 30(2):321-329.
13. Gardulf A., Hammarstrom L., Smith C.I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991, 338(8760):162-166.
14. Chapel H., Brennan V., Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol 1988, 73(1):160-162.
15. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010, 30(2):301-307.
16. UK Medical Research Council Hypogammaglobulinaemia in the United Kingdom. Special Report Series 1971, UK Medical Research Council, London (HMSO), p. 310.
17. Liu Z., Albon E., Hyde C. The effectiveness and cost-effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation 2006, Birmingham: West Midlands Health Technology Assessment Group, Dept of Public Health & Epidemiology, University of Birmingham, p. 54.
18. Chapel H., Lucas M., Lee M., et al. Common variable Immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008, 112(2):277-286.
19. Roitman C.M., Schroeder H., Berger M., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIVSD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003, 3(9):1325-1333.
20. Aghamohammadi A., Moin M., Farhoudi A., et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004, 40(2):113-118.
21. Busse P.J., Razvi S., Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002, 109(6):1001-1004.
22. de Gracia J., Vendrell M., Alvarez A., et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004, 4(6):745-753.
23. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001, 135(3):165-174.
24. Cunningham-Rundles C., Siegal F.P., Smithwick E.M., et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984, 101(4):435-439.
25. Plebani A., Soresina A., Rondell R., et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002, 104(3):221-230.
26. Quinti I., Soresina A., Guerra A., et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome In patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011, 31(3):315-322.
27. Chapel H.M., Spicketl G.P., Ericson D., et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20(2):94-100.
28. Borte M., Bernatowska E., Ochs H.D., et al. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol 2011, 164(3):357-364.
29. Hoffmann F., Grimbacher B., Thiel J., et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010, 15(6):238-245.
30. Berger M., Rojavin M., Kiessling P., et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011, 139(2):133-141.
31. Lucas M., Lee M., Lortan J., et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010, 125(6):1354-1360. e4.
32. Orange J.S., Grossman W.J., Navickis R.J., et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010, 137(1):21-30.
33. Khan S., Grimbacher B., Boecking C., et al. Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy. Drug Metab Lett 2011, 5(2):132-136.
34. Yong P.L., Boyle J., Ballow M., et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010, 135(2):255-263.
35. Roifman C.M., Berger M., Notarangelo L.D. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin North Am 2008, 28(4):875-876. x.
36. Shehata N., Palda V., Bowen T., et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010, 24(Suppl 1):528-550.
37. Rachid R., Bonilla F.A. The role of anti-lgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012, 129(3):628-634.
38. Feldmeyer L., Benden C., Haile S.R., et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol 2010, 90(5):494-497.
39. Chapel H.M., Christie J.M., Peach V., et al. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001, 99(3):320-324.
40. Quinti I., Pierdominici M., Marziali M., et al. European surveillance of immunoglobulin safety-results of Initial survey of 1243 patients with primary Immunodeficiencies In 16 countries. Clin Immunol 2002, 104(3):231-236.
41. Spickett G.P., Askew T., Chapel H.M. Management of primary antibody deficiency by consultant immunologists in the United Kingdom: a paradigm for other rare diseases. Qual Health Care 1995, 4(4):263-268.
42. Blore J., Haeney M.R. Primary antibody deficiency and diagnostic delay. BMJ 1989, 298(6672):516-517.
43. Seymour B., Miles J., Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005, 58(5):546-547.
44. Chapel H.M. Consensus on diagnosis and management of primary antibody deficiencies. Consensus panel for the diagnosis and management of primary antibody deficiencies. BMJ 1994, 308(6928):581-585.
45. Kainulainen L., Nlkoskelainen J., Ruuskanen O. Diagnostic findings in 95 Finnish patients with common variable immunodeficiency. J Clin Immunol 2001, 21(2):145-149.
46. Wang J., Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable Immunodeficiency (CVID). J Autoimmun 2005, 25(1):57-62.
47. Sordet C., Cantagrel A., Schaeverbeke T., et al. Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine 2005, 72(6):503-514.
48. Wood P. Primary antibody deficiency syndromes. Ann Clin Biochem 2009, 46(Pt 2):99-108.
49. Wood P., Stanworth S., Burton J., et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007, 149(3):410-423.
50. Mellemkjaer L., Hammarstrom L., Andersen V., et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002, 130(3):495-500.
51. Gardulf A., Bjorvell H., Gustafson R., et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993, 92(2):200-204.
52. Bergner M., Bobbitt R.A., Carter W.B., et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981, 19(8):787-805.
53. Berger M., Murphy E., Riley P., et al. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010, 103(9):856-863.
54. Howard V., Greene J.M., Pahwa S., et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006, 118(2-3):201-208.
55. Lederman H.M., Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985, 64(3):145-156.
56. Aghamohammadi A., Montazeri A., Abolhassani H., et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol 2011, 10(1):47-51.
57. Tcheurekdjian H., Palermo T., Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2004, 93(2):160-165.
58. Galli E., Barbieri C., Cantani A., et al. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up. Ann Allergy 1990, 64(2 Pt 1):147-150.
59. Gardulf A., Andersen V., Bjorkander J., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345(8946):365-369.
60. Hogy B., Kelnecke H.O., Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005, 6(1):24-29.
61. Lippert B., Berger K., Bemtorp E., et al. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis 2005, 16(7):477-485.
62. Wakim M., Shah A., Arndt P.A., et al. Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency. Am J Hematol 2004, 76(2):152-155.
63. Mahevas M., Le Page L., Salle V., et al. Efficiency of rituximab In the treatment of autoimmune thrombocytopenic purpura,; associated with common variable immunodeficiency. Am J Hematol 2006, 81(8):645-648.
64. EI-Shanawany T.M., Williams P.E., Jolles S. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol 2007, 60(6):715-718.
65. Al-Ahmad M., Al-Rasheed M., Al-Muhani A. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency. J Investig Allergol Clin Immunol 2010, 20(3):259-262.
66. Gobert D., Bussel J.B., Cunningham-Rundles C. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011, 155(4):498-508.
67. Hatab A.Z., Ballas Z.K. Caseating granulomatous disease in common variable immunodeficiency treated with Infliximab. J Allergy Clin Immunol 2005, 116(5):1161-1162.
68. Thatayatikom A., Thatayatikom S., White A.J. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol 2005, 95(3):293-300.
69. Malbran A., Juri M.C., Fernandez Romero D.S. Common variable immunodeficiency and granulomatosis treated with infliximab. Clin Immunol 2010, 134(3):359-360.
70. Kaplan A.P., Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104(3):193-204.
71. Pickering R.J., Good R.A., Kelly J.R., et al. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969, 1(7590):326-330.
72. Cohen G., Peterson A. Treatment of hereditary angioedema with frozen plasma. Ann Allergy 1972, 30(12):690-692.
73. Kunschak M., Engl W., Maritsch F., et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998, 38(6):540-549.
74. Kaplan A.P. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010, 126(5):918-925.
75. Bork K., Frank J., Grundt B., et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007, 119(6):1497-1503.
76. Krause K., Metz M., Zuberbier T., et al. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. J Dtsch Dermatol Ges 2010, 8(4):272-274.
77. Cicardi M., Banerji A., Bracho F., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363(6):532-541.
78. Lumry W.R., Li H.H., Levy R.J., et al. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011, 107(6):529-537.
79. Zuraw B.L., Busse P.J., White M., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010, 363(6):513-522.
80. Hofstra J.J., Budde I.K., van Twuyver E., et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor(R)): Multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol 2012, 142(3):280-290.
81. van Doom M.B., Burggraaf J., van Dam T., et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005, 116(4):876-883.
82. Zuraw B., Cieardi M., Levy R.J., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010, 126(4):821-827. e14.
83. Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther 2008, 8(8):1187-1199.
84. Cieardi M., Levy R.J., McNeil D.L., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010, 363(6):523-531.
85. Levy R.J., Lumry W.R., McNeil D.L., et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104(6):523-529.
86. Levi M., Choi G., Picavet C., et al. Self-administration of C1-inhibltor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006, 117(4):904-908.
87. Bygum A., Andersen K.E., Mikkelsen C.S. Self-administration of intravenous C1-inhlbitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009, 19(2):147-151.
88. Tallroth G.A. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol 2011, 154(4):356-359.
89. Lunn M., Santos C., Craig T. Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety. J Blood Med 2010, 1:163-170.
90. Cicardi M., Bork K., Caballero T., et al. Evidence based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012, 67(2):147-157.